Neurocrine Biosciences (NASDAQ:NBIX) Receives “Buy” Rating from HC Wainwright

Neurocrine Biosciences (NASDAQ:NBIX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $190.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 49.96% from the company’s previous close.

A number of other research analysts also recently weighed in on NBIX. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. BMO Capital Markets cut their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Royal Bank of Canada cut their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Finally, Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $165.18.

Neurocrine Biosciences Trading Down 0.1 %

Shares of NASDAQ NBIX opened at $126.70 on Monday. Neurocrine Biosciences has a 1 year low of $110.95 and a 1 year high of $157.98. The firm’s 50-day moving average is $121.75 and its 200-day moving average is $130.62. The firm has a market capitalization of $12.83 billion, a PE ratio of 33.97 and a beta of 0.34.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC raised its stake in Neurocrine Biosciences by 34.0% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,357 shares of the company’s stock valued at $875,000 after acquiring an additional 1,613 shares during the period. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Neurocrine Biosciences by 6.6% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 2,710 shares of the company’s stock worth $373,000 after buying an additional 168 shares during the last quarter. Pallas Capital Advisors LLC boosted its holdings in shares of Neurocrine Biosciences by 26.4% during the 2nd quarter. Pallas Capital Advisors LLC now owns 3,098 shares of the company’s stock worth $447,000 after buying an additional 647 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Neurocrine Biosciences by 14.7% during the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after buying an additional 92 shares during the period. Finally, Fifth Third Wealth Advisors LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at about $435,000. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.